James Yan
Chief Tech/Sci/R&D Officer bei ZAI LAB LIMITED
Aktive Positionen von James Yan
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ZAI LAB LIMITED | Chief Tech/Sci/R&D Officer | 01.04.2020 | - |
| Chinese Society of Toxicology | Corporate Officer/Principal | - | - |
Karriereverlauf von James Yan
Ehemalige bekannte Positionen von James Yan
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Hutchison MediPharma Ltd.
 Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Corporate Officer/Principal | 01.01.2009 | 01.01.2011 |
Ausbildung von James Yan
| Peking Union Medical College | Doctorate Degree |
Statistik
International
| China | 5 |
Operativ
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ZAI LAB LIMITED | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Hutchison MediPharma Ltd.
Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Health Technology |
| Chinese Society of Toxicology |
